Frankfurt - Delayed Quote EUR

SCYNEXIS, Inc. (135A.F)

0.7910

+0.0100

+(1.28%)

As of 8:20:04 AM GMT+2. Market Open.

SCYNEXIS to Present Preclinical Data on Second Generation IV/Oral Fungerp SCY-247 at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID)

JERSEY CITY, N.J., April 08, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical efficacy data on its second-generation fungerp candidate SCY-247 at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global) in Vienna, Austria being held from April 11-15, 2025. SCY-247 is being developed to

GlobeNewswire 8 days ago

SCYX
SCYNEXIS Full Year 2024 Earnings: Misses Expectations

SCYNEXIS ( NASDAQ:SCYX ) Full Year 2024 Results Key Financial Results Net loss: US$21.3m (down by 132% from US$67.0m...

Simply Wall St. last month

SCYX
SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update

The Phase 1 trial of the second-generation triterpenoid antifungal SCY-247, initiated in December of 2024, continues and results are expected in Q3 of 2025.Four presentations for SCY-247 were accepted by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global) congress, April 11-15, 2025 in Vienna, Austria.SCYNEXIS continues to make progress towards the restart of the Phase 3 MARIO study in invasive candidiasis. The Company anticipates the restart, pending the FDA’s

GlobeNewswire last month

SCYX
SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections

JERSEY CITY, N.J., Dec. 18, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it has completed the dosing of the first cohort of subjects in its Phase 1 trial of SCY-247, the Company’s second-generation triterpenoid antifungal in development for the treatment of severe invasive fungal infections. “We are pleased to advance our potent, second

GlobeNewswire 3 months ago

SCYX
SCYNEXIS Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

SCYNEXIS ( NASDAQ:SCYX ) Third Quarter 2024 Results Key Financial Results Revenue: US$660.0k (down 63% from 3Q 2023...

Simply Wall St. 5 months ago

SCYX
Scynexis: Q3 Earnings Snapshot

JERSEY CITY, N.J. (AP) — Scynexis Inc. SCYX) on Wednesday reported a loss of $2.8 million in its third quarter. On a per-share basis, the Jersey City, New Jersey-based company said it had a loss of 6 cents.

Associated Press Finance 5 months ago

SCYX
SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Clinical study reports for the FURI, CARES and NATURE trials in refractory or resistant invasive fungal infections were delivered to GSK, triggering a $10 million development milestone payment to SCYNEXIS, received in Q3 2024. SCY-247 preclinical studies were presented at medical conferences and continue to show potent and broad antifungal activity. Phase 1 study initiation is anticipated in Q4 2024. SCYNEXIS ended Q3 2024 with cash, cash equivalents and investments of $84.9 million, including t

GlobeNewswire 5 months ago

SCYX
Investors in SCYNEXIS (NASDAQ:SCYX) have unfortunately lost 89% over the last five years

Long term investing works well, but it doesn't always work for each individual stock. We really hate to see fellow...

Simply Wall St. 5 months ago

SCYX
SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit

JERSEY CITY, N.J., Oct. 10, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced David Angulo, M.D., President and Chief Executive Officer, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit on Thursday, October 17, at 11:30 A.M. ET. Maxim Healthcare Virtual Summit Details: Format:Fireside chatDate:Thursday, October 17,

GlobeNewswire 6 months ago

SCYX
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024

JERSEY CITY, N.J., Oct. 03, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced upcoming presentations of preclinical efficacy and pharmacokinetic data on its second-generation fungerp candidate SCY-247 at IDWeek 2024 taking place in Los Angeles, CA from October 16-19, 2024. Presentation details can be found below: Oral Presentation: Title:Efficacy

GlobeNewswire 6 months ago

SCYX
SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference

JERSEY CITY, N.J., Aug. 27, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced David Angulo, M.D., President and Chief Executive Officer, will make a corporate presentation as well as host 1x1 meetings at the H. C. Wainwright 26th Annual Global Investment Conference on Wednesday, September 11 at 10:00 A.M. ET. H. C. Wainwright 26th Annual Global I

GlobeNewswire 7 months ago

SCYX
SCYNEXIS Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

SCYNEXIS ( NASDAQ:SCYX ) Second Quarter 2024 Results Key Financial Results Revenue: US$736.0k (down 99% from 2Q 2023...

Simply Wall St. 8 months ago

SCYX
Scynexis: Q2 Earnings Snapshot

JERSEY CITY, N.J. (AP) — Scynexis Inc. SCYX) on Thursday reported a loss of $14.5 million in its second quarter. The Jersey City, New Jersey-based company said it had a loss of 30 cents per share.

Associated Press Finance 8 months ago

SCYX
SCYNEXIS Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Clinical study reports for the FURI, CARES and NATURE trials in refractory or resistant invasive fungal infections were delivered to GSK, triggering a $10 million development milestone payment to SCYNEXIS which we expect to receive in Q3 2024. SCY-247’s IND-enabling activities continue to progress. Pre-clinical in vitro and in vivo studies, presented at several medical conferences, have shown potent and broad antifungal activity. Phase 1 study initiation is planned for Q4 2024. SCYNEXIS ended Q2

GlobeNewswire 8 months ago

SCYX
SCYNEXIS to Receive $10 Million Milestone Payment from GSK Triggered by Delivery of Completed FURI, CARES and NATURE Clinical Study Reports

Reiterating cash runway of > 2 yearsJERSEY CITY, N.J., July 23, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it will receive a $10 million development milestone payment under its exclusive license agreement with GSK for ibrexafungerp. The milestone payment is triggered by the delivery of final clinical study reports for the completed FU

GlobeNewswire 8 months ago

SCYX
3 Stocks Under $10 With the Potential for Massive Gains

Investing in small-cap stocks can be a gateway to high returns, mainly when these companies exhibit strong growth fundamentals and strategic market positioning. Here, the focus is on three stocks to buy under $10. The fundamentals behind these companies may diversify portfolios with high potential. These companies’ financial performance and strategic initiatives explain why these small-cap stocks are poised for high gains. The first one has consistently demonstrated impressive top-line growth, d

InvestorPlace 8 months ago

SOFI

INGN

SCYX
Hidden Gems: 3 Under-$10 Stocks Poised for 500% Growth by 2025

The ability to recognize possibilities while investing can frequently be the difference between stagnation and growth in an unstable and changing economic environment. Here are three exciting stocks in technology, insurance, and medicines. Leading the pack among these chances is the first, which has cleverly turned to utilize partnerships and licensing agreements to generate income. These tactical changes highlight a practical reaction to the difficulties and expenses of medicine marketing, even

InvestorPlace 10 months ago

IMMR

HRTG

SCYX
3 Stocks Under $10 With Mammoth Growth Prospects

Finding good prospects is like hunting gold in the fast-paced world of investing. Three stocks stand out in this hunt, all under $10, with significant growth potential. These companies operate in a variety of industries, including technology and healthcare. They offer a unique opportunity to profit from rapid revenue growth, strong financial stability and well-thought-out development strategies. With a robust organic revenue increase in the first quarter and a solid focus on the hyaluronic acid

InvestorPlace 10 months ago

BVS

IMMR

SCYX
SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update

SCY-247’s IND-enabling activities continue to progress, with initiation of Phase I anticipated in the second half of 2024Clinical study reports for the FURI, CARES and NATURE trials in refractory invasive fungal infections remain on track for delivery to GSK in mid 2024, which would trigger a $10 million development milestone payment to SCYNEXISSCYNEXIS ended Q1 2024 with cash, cash equivalents and investments of $94.2 million and projects a cash runway of more than two years JERSEY CITY, N.J.,

GlobeNewswire 11 months ago

SCYX
Investors in SCYNEXIS (NASDAQ:SCYX) have unfortunately lost 87% over the last five years

Long term investing is the way to go, but that doesn't mean you should hold every stock forever. We don't wish...

Simply Wall St. 11 months ago

SCYX

Performance Overview

Return	135A.F	S&P 500 (^GSPC)
YTD	-15.08%	-10.30%
1-Year	-39.20%	+5.05%
3-Year	-74.41%	+20.10%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

SCYNEXIS, Inc. (135A.F)

SCYNEXIS to Present Preclinical Data on Second Generation IV/Oral Fungerp SCY-247 at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID)

SCYNEXIS Full Year 2024 Earnings: Misses Expectations

SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update

SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections

SCYNEXIS Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Scynexis: Q3 Earnings Snapshot

SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Investors in SCYNEXIS (NASDAQ:SCYX) have unfortunately lost 89% over the last five years

SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024

SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference

SCYNEXIS Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Scynexis: Q2 Earnings Snapshot

SCYNEXIS Reports Second Quarter 2024 Financial Results and Provides Corporate Update

SCYNEXIS to Receive $10 Million Milestone Payment from GSK Triggered by Delivery of Completed FURI, CARES and NATURE Clinical Study Reports

3 Stocks Under $10 With the Potential for Massive Gains

Hidden Gems: 3 Under-$10 Stocks Poised for 500% Growth by 2025

3 Stocks Under $10 With Mammoth Growth Prospects

SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update

Investors in SCYNEXIS (NASDAQ:SCYX) have unfortunately lost 87% over the last five years

Performance Overview